• News
  • Events
  • Case Studies
  • Publications
  • Press Office
  • Contact
  • Coronavirus (COVID-19)
  • OxLEP Business
OxLEP OxLEP OxLEP OxLEP
  • About
    • About OxLEP
    • About Oxfordshire
    • Our Team
    • Our Board and sub-groups
    • Our Capital Programmes
      • Getting Building Fund
      • Local Growth Fund
      • City Deal
      • Growing Places Fund
    • Our Meetings
    • Our Strategies
    • Our Governance
    • The LEP Network
    • Our Vacancies
  • Skills
    • Our Approach
    • Our Programmes
    • Business Volunteering
    • Skills and Labour Market Information
    • Skills Capital Infrastructure
    • Oxfordshire Apprenticeship Awards
  • Business
    • Our Approach
    • Our business support
    • Our impact on business
    • Brexit support
    • Invest in Oxfordshire
  • News
  • Events
  • Case Studies
  • Publications
  • Press Office
  • Contact
  • Coronavirus (COVID-19)
  • OxLEP Business

Search form

News

You are here

  • Home
  • News
  • Scancell expands its R&D capabilities with new facilities at The Oxford Science Park

OxLEP uses cookies to capture data, allowing us to improve our site experience for everyone.

To learn about how we use cookies please visit our privacy policy

Posted on 19th October 2021

Scancell expands its R&D capabilities with new facilities at The Oxford Science Park

Scancell expands its R&D capabilities with new facilities at The Oxford Science Park

Scancell Holdings PLC, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has expanded its R&D capabilities by taking new laboratory and office space in the Bellhouse Building at The Oxford Science Park, one of the UK’s leading parks for science and technology companies.

The new premises, which are complementary to Scancell’s laboratories in the Biodiscovery Institute at the University of Nottingham, will allow the company to further accelerate the development of its portfolio of immunotherapies.

Scancell, which raised £46 million last year to drive its pipeline through clinical trials, is now working from 1,900 sq ft of laboratory space and 1,800 sq ft of office facilities at the science park. Scancell currently employs just over 40 staff, of which approximately half are located in the new premises and plans to recruit additional people to its clinical and product development teams in the next 12 months.

The company is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with innovative products in multiple cancer indications and a vaccine in development for COVID-19.

The new laboratories will support the company’s clinical trial activities and provide analytical and formulation facilities for future product development.

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: “The Oxford Science Park is the perfect location for Scancell’s expansion, with access to an excellent local talent pool as we grow the business. We are excited to be part of the creative and collaborative group of companies located in the Park and look forward to further developing our innovative products at this new site.”

Rory Maw, CEO of The Oxford Science Park, said: “We are delighted that Scancell has chosen to locate its new R&D facility at The Oxford Science Park, the Company’s first laboratories outside of the university setting. Scancell joins Enara Bio, MoA Technology and Sitryx in the Bellhouse Building.

"With its leading research in cancer and infectious disease, the Company is a great addition to the innovation community here. This is exciting news for TOSP, following the announcement of our partnership with GIC to accelerate development of the Park.”

Find out more on Oxford Science Park

Rob Panting

By Rob Panting 526 articles

[email protected]​oxfordshirelep.com
01865 897195
07748 333402

Other General News

8th August 2022

OX to ZERO summit: Oxfordshire’s world-leading solutions to reaching net zero

5th August 2022

Local Growth Fund Case Study: Upstream Flood Storage at Northway and Marston

29th July 2022

Local Growth Fund Case Study: Didcot Station Multi-Storey Car Park

22nd July 2022

Local Growth Fund Case Study: The Advanced Skills Centre

21st July 2022

Green light for 'Nebula R&D scheme at Milton Park

21st July 2022

'Meanwhile in Oxfordshire..' Case Study: The family of foodies cooking up one of the top-3 restaurants in Oxford from a ‘Meanwhile’ co-working space

Stay up to date on the latest stories and events with our newsletter

Sign Up
youtubetwitterlinkedinfacebookinstagram
  • About
    • About OxLEP
    • About Oxfordshire
    • Our Team
    • Our Board and sub-groups
    • Our Capital Programmes
    • Our Meetings
    • Our Strategies
    • Our Governance
    • The LEP Network
    • Our Vacancies
  • Skills
    • Our Approach
    • Our Programmes
    • Business Volunteering
    • Skills and Labour Market Information
    • Skills Capital Infrastructure
    • Oxfordshire Apprenticeship Awards
  • Business
    • Our Approach
    • Our business support
    • Our impact on business
    • Brexit support
    • Invest in Oxfordshire
The Oxfordshire Local Enterprise Partnership (OxLEP) Ltd HQ Building Thomson Avenue Harwell Campus OX11 0GD
[email protected]​oxfordshirelep.com
0345 241 1196
  • News
  • Events
  • Case Studies
  • Publications
  • Press Office
  • Contact
  • Coronavirus (COVID-19)
  • OxLEP Business
  • Privacy Policy
  • Terms & Conditions
© 2022 OxLEP
Website by Indulge